KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,812,977 | +14.5% | 312,553 | 0.0% | 0.32% | -15.5% |
| Q1 2023 | $2,456,667 | +116164.4% | 312,553 | 0.0% | 0.37% | +17.6% |
| Q4 2022 | $2,113 | -100.0% | 312,553 | 0.0% | 0.32% | -56.4% |
| Q3 2022 | $4,535,000 | +47.4% | 312,553 | 0.0% | 0.73% | +12.2% |
| Q2 2022 | $3,076,000 | -33.2% | 312,553 | 0.0% | 0.65% | -36.8% |
| Q1 2022 | $4,607,000 | +11.4% | 312,553 | 0.0% | 1.03% | +7.4% |
| Q4 2021 | $4,135,000 | -24.2% | 312,553 | 0.0% | 0.96% | -33.4% |
| Q3 2021 | $5,454,000 | +0.4% | 312,553 | +37.9% | 1.44% | -24.0% |
| Q2 2021 | $5,431,000 | -1.4% | 226,671 | +5.7% | 1.89% | -13.8% |
| Q1 2021 | $5,510,000 | – | 214,467 | – | 2.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |